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C YTOCHROME P-450s (CYPs) comprise a superfamily of heme-thiolate proteins. They function as monooxygenases and display diverse functions, from the synthesis and degradation of biological signaling molecules, such as steroid hormones and fatty acid derivatives, to the metabolism of xenobiotic chemicals including pharmaceutical drugs and environmental contaminants and carcinogens. The metabolic activity of these enzymes is a widely employed defense mechanism against exposure to toxic xenobiotics (1) . A central part of this defense is the adaptative increase of CYP gene expression (induction), which leads to enhanced metabolism and suppression of the pharmacological action of drugs (2) . The mechanisms of induction of the major drug metabolizing CYP genes have been studied intensively, and recent findings indicate that a common pathway is used: exposure to drugs activates specific members of the nuclear receptor superfamily, which in turn bind their cognate DNA elements and stimulate the transcription of CYP target genes (3) . This leads to increased synthesis of CYP enzymes and enhanced metabolism and clearance of the drugs. These receptors include members of the nuclear receptor superfamily of ligand-activated transcription factors: CAR (constitutive androstane receptor, NR1I3), pregnane X receptor, NR1I2, and PPAR (peroxisome proliferator-activated receptor, NR1C1-3).
CAR was initially characterized as a constitutive activator of a set of retinoic acid response elements (4) . It binds DNA, generally composed of a direct repeat of the AGGTCA hexamer separated by four nucleotides (nt) (DR4), as a heterodimer with RXR (retinoid X receptor) (4, 5) . Recently, CAR has been identified as the mediator of the effects of phenobarbital (PB) (6, 7) . PB is the prototype of a large group of structurally diverse xenobiotic chemicals that induce CYP genes within the CYP2A, CYP2B, CYP2C, and CYP3A subfamilies, with the CYP2B genes being the most effectively induced (8) . The PB-responsive enhancers of rat CYP2B2, mouse cyp2B10, and human CYP2B6 contain two nuclear receptor binding sites (NR1 and NR2), flanking a nuclear factor 1 binding site (9) . In PBtreated mice, the binding of the CAR to the NR1 site is greatly increased (10) . In fact, in contrast to other nuclear receptors, CAR is sequestered in the cytosol and translocates into the nucleus upon activation, presumably through several steps of phosphorylation (10) . Only a few molecules among CYP inducers have been shown to bind directly to human CAR. These include androstenol, clotrimazole, and 5-␤-pregnane-3,20-dione (11) . However, both androstenol and clotrimazole appear to be deactivators rather than activators of hCAR, whereas 5-␤-pregnane-3,20-dione appears as a true activator. PB, a compound that has been shown to induce CAR translocation, is not a ligand of CAR (11, 12) . However, CAR is essential for the PB effect as demonstrated in CAR Ϫ/Ϫ mice (13) . CAR has been found to transactivate several major hepatic CYPs involved in drug metabolism in humans: including CYP2B6 (9), CYP2C9 (14) , and CYP3A4 (9, 15) . Indeed, CAR plays a general role in regulating a number of drug/steroid-metabolizing enzymes, as it also regulates the expression of cytochrome P450 reductase (16) , which represents an essential component of CYP-dependent metabolic activity. On the other hand, other unexplained functions of CAR have been reported, notably the increase in liver weight and DNA synthesis in response to PB (13) .
In addition to the lack of knowledge of the mechanisms involved in CAR activation by chemicals, very little is known about its transcriptional regulation. The mouse CAR gene has two known mRNA isoforms (mCAR1 and mCAR2). The mCAR1 is closely related to the human CAR. In contrast, mCAR2 is truncated, lacking a C-terminal region of the ligand binding domain, resulting from alternative exon splicing leading to the loss of exon 8 (5) . In humans, CAR is predominantly expressed in hepatocytes, and the most prominent mRNA band migrates as a rather broad band spanning approximately 1.3-1.7 kb (4). The human CAR (hCAR) isoform homologous to mCAR2 has not been clearly identified, even though its existence is suspected (17) . It has long been known that dexamethasone, or glucocorticoids, are required for efficient PB response (3, (18) (19) (20) (21) (22) , whereas proinflammatory cytokines, such as IL-1 or IL-6, decrease PB-mediated CYP induction (23) (24) (25) . Indeed, we previously reported that CAR mRNA and protein expression are induced in cultured human hepatocytes by glucocorticoids, such as dexamethasone, prednisone, and hydrocortisone (17) . The results obtained in this earlier work strongly suggested that a ligandactivated glucocorticoid receptor (GR) positively regulates hCAR gene expression. In contrast, we have shown that IL-6 produces a dramatic decrease of CAR mRNA expression (26) . From these findings, we proposed that CAR expression should be considered as a limiting factor of CYP induction, subject to cross-talk interactions with other signaling pathways.
As an initial step in the investigation of the transcriptional regulatory mechanisms involved in CAR expression, we cloned the 5Ј-flanking region of the hCAR gene. In this report, we describe a distal glucocorticoid response element (GRE) located within the CAR promoter and present evidence that this element is capable of conferring transcriptional activation via the glucocorticoid pathway.
RESULTS

Genomic Structure of the hCAR Gene
The hCAR mRNA [(4), GenBank accession no. NM005122) sequence was used to search the BLAST human genome NCBI database. The corresponding hCAR gene was found to map to chromosome 1q21-23. This region is located on the contig NT026945 spanning approximately 8.5 kb. The genomic structure of the CAR gene ( Fig. 1 ) consists of nine exons; exon 2 through exon 9 contain the coding region of 348 amino acids (GenBank accession no. NP005113) as determined by aligning the cDNA sequence to the genomic sequence. Its closest genes are the apolipoprotein A-II and the myelin protein zero.
The initial CAR cDNA reported by Baes et al. (4) has a different 110-nt-long 5Ј-sequence compared with the contig sequence. In fact, we observed that this region maps very well (100%) to a portion of the chromosome X (contig NT025273, data not shown). Thus, this region seems to represent a contamination of the cDNA library used by these authors. In support of this, using RT-PCR performed with a primer corresponding to this region [untranslated region (UTR) 55-76 forward primer], we failed to amplify any band from two different human liver RNAs. In contrast, using the same approach with a primer downstream of this region, UTR 179-198, we successfully amplified the expected bands (data not shown). Similar results were obtained with 5Ј-rapid amplification of the cDNA end (5Ј-RACE) (Fig. 3B) . These data strongly suggest that the untranslated region of hCAR is 110 nt shorter than previously described.
Identification and Chromosomal Location of the hCAR Gene and Promoter
We cloned about 4.9 kb of the hCAR promoter using genomic PCR with primers designed according to the sequence indicated in the contig NT026945. Restriction analysis (data not shown) and full-length sequencing confirmed that the fragment cloned was similar to the expected contig sequence, and only a few differences were found (two mismatches/4.9 kb). Chromosomal assignment was confirmed by fluorescence in situ hydridization (FISH) of normal metaphase chomosomes using probes generated both from the cDNA and the cloned hCAR gene promoter. As shown in Fig. 2 , we observed a strict colocalization between the NR1I3 cDNA and the promoter probe signal on chromosome 1, in an area corresponding to 1q21 (19 metaphases counted with the cDNA probe and 13 metaphases with the gene promoter probe). Significant secondary signals were not observed but background was present in many metaphases.
Transcription Start Site
The transcriptional start site was first determined by primer extension assay using a 28-nt end-labeled primer, which hybridizes 48 nt upstream of the ATG codon. Two major bands were detected in human liver RNA (Fig. 3A) , which place the transcriptional start point Ϫ160 bp upstream of the ATG codon. Using 5Ј-RACE PCR, we obtained results similar to those summarized in Fig. 3B . The apparent start site of transcription identified by these studies lies approximately 30 nt from a TATA-like box (CATAAAA). This atypical TATA box has already been identified in the gene promoter of a hepatic enzyme that is a CAR target gene, the mouse cyp2B10 (27) . To confirm that the 5Ј-flanking sequences of the CAR gene can confer promoter activity, different 5Ј-flanking regions of CAR were cloned upstream of a promoterless luciferase reporter gene (Ϫ4711/ϩ144 to Ϫ120/ϩ144pGL3b). The positions indicated are based on the transcription start site predicted by the contig NT026945 sequence and determined by both primer extension analysis and 5Ј-RACE results. These constructs were transfected in the human hepatocarcinoma HepG2 cell line. As indicated in Fig. 3C , full activity was observed with a rather short fragment from Ϫ237 to ϩ144, with a further deletion to Ϫ120 showing significantly decreased expression. Thus, these results map the minimal CAR sequences necessary for the promoter activity in HepG2 cells to approximately Ϫ237 to ϩ144, mostly contributed by sequences between Ϫ237 and Ϫ120. Deletion of the proximal region Ϫ337/ϩ144 resulted in a dramatic decrease in luciferase activity of the Ϫ4771/Ϫ335pGL3b construct, to a level similar to that observed with the parental pGL3basic vector, as this construct does not contain a transcription start site. Analysis of the Ϫ237 to Ϫ120 CAR promoter DNA sequence, revealed numerous potential hepatocytespecific transcription factor binding sites such as CCAAT enhancer binding protein-␣, hepatocyte nuclear factor 3, and hepatocyte nuclear factor 4, consistent with the liver-enriched expression of CAR.
Identification of a Functional GlucocorticoidResponsive Element in the Distal Regulatory Region of Gene CAR
In recent work, we observed that induction of CAR mRNA by dexamethasone paralleled that of TAT, a gene product known to be controlled by GR (28) , in terms of time and concentration dependence in primary human hepatocytes. This glucocorticoid stimulation was inhibited by RU486, a specific glucocorticoid antagonist. Moreover, the induction was not suppressed by cycloheximide treatment of the hepatocytes, indicating that it was mediated by a preexisting GR (17) . This prompted us to look for a functional GRE in the CAR promoter gene. For this purpose, the 5Ј-flanking region of CAR from Ϫ4711 to ϩ144 was cloned upstream of a luciferase reporter gene (Ϫ4711/ ϩ144pGL3b). This reporter plasmid and the parental pGL3basic vector were then transfected into human hepatocytes (which express endogenous GR), and hepatic (HepG2) and nonhepatic (CV1, monkey fibroblast) cell lines in which GR expression is undetectable, with or without a plasmid expressing human GR (pSG5-hGR). Cells were treated for 16 h in the presence or absence of 100 nM dexamethasone, and the luciferase activity was measured. As shown in Fig. 4 , dexamethasone treatment provoked a strong induction (6-fold) of luciferase activity of the Ϫ4711/ ϩ144pGL3b construct in human hepatocytes, whereas the activity of the empty vector was unaffected. In HepG2 or CV1 cell lines, dexamethasonemediated induction was observed only in the presence of hGR cotransfection. These results suggest that GR is required for hCAR expression by dexamethasone. The magnitude of dexamethasone-induced luciferase gene transcription is similar to the magnitude of hCAR mRNA stimulation in cultured human hepatocytes [6-fold induction (17)], suggesting that transcriptional activation of this region is sufficient to account for the effect of dexamethasone on steady state hCAR mRNA levels.
In HepG2 cells, as shown in Fig. 5A , plasmids Ϫ4711/ϩ144pGL3b or pTAT-GRE2-TK-luc (harboring two copies of the GRE from TAT) exhibited parallel responses to increasing concentrations of dexamethasone in the presence of hGR cotransfection, a plateau being reached at 10-100 nM. These concentrations are known to saturate hGR. As expected, dexamethasone-or hydrocortisone-mediated induction was inhibited by the GR antagonist mifepristone (RU486) in a dose-dependent manner (Fig. 5B) . Finally, cotransfection of the dominant negative human GR-DNA-binding domain (DBD) (GR amino acids 1-500) expression vector, which contains only the DBD of the GR, provoked a dose-dependent inhibition of ligandactivated GR-mediated induction (Fig. 5C ).
As these results strongly suggested the presence of a GRE located on the Ϫ4710/ϩ144 region of the CAR promoter, a more detailed analysis of hGR-mediated transactivation of CAR promoter deletion constructs was undertaken. For this purpose, several plasmids containing deletion constructs were generated. The results are presented in Fig. 6A . No significant induction of the reporter gene was observed without hGR transfection in any of the constructs examined. In contrast, when these plasmids were cotransfected with the hGR expression vector, similar induction (6-to 8-fold) was observed in response to 100 nM dexamethasone for Ϫ4477/ϩ144pGL3b, Ϫ4561/ϩ144pGL3b, and Ϫ4711/ϩ144pGL3b constructs. However, a major decrease in luciferase activity was observed with the construction Ϫ4410/ϩ144pGL3b and shorter constructs. Similar results were obtained in CV1 cells (data not shown). To examine whether the GC-responsive domain exhibited enhancer properties, fragments of the 5Ј-flanking region were inserted downstream of a minimal simplex virus thymidine kinase promoter vector (pGL3TK) and cotransfected with GR in HepG2 cells (Fig. 6B) . A strong and inducible expression (20-fold increase) was observed with Ϫ4711/Ϫ61pGL3TK, Ϫ4711/Ϫ2146pGL3TK, Ϫ47711/Ϫ4311pGL3TK, Ϫ4561/ Ϫ4311pGL3TK, and Ϫ4477/Ϫ4311pGL3TK constructs upon dexamethasone treatment. In contrast, no induction was observed with Ϫ4410/Ϫ4311pGL3TK or Ϫ4410/ Ϫ61pGL3TK constructs. These results show that there is a glucocorticoid-responsive element in the distal hCAR promoter, between Ϫ4477 and Ϫ4410 nt upstream of the transcription start site. 
Characterization of the hCAR-GRE
Computer analysis of this region demonstrated that there is no perfect GRE in this 67-nt-long sequence, but that the central region (Ϫ4447/Ϫ4432) contains two putative imperfect GRE half-sites (indicated by capital letters) separated by 3 nt (GGAACAacaAG GGCA, Fig. 7A ). Moreover, this region contains all the relevant guanines shown to be necessary for GR binding [G or complementary C that are underlined; Beato, M., personal communication (29)]. To evaluate the role of these sites, they were mutated sequentially, and the corresponding 33-nt-long oligonucleotides (Ϫ4458/ Ϫ4425) were cloned downstream of the pGL3TK vector.
Plasmids hCAR-GREwt-pGL3TK (wild-type sequence), hCAR-GREinv-pGL3TK (wild-type sequence in inverse orientation), hCAR-MUT1-pGL3TK (muta- A, To map the transcription start site, primer extension analysis was carried out using total RNA from human hepatocytes. Lane 1 represents the extended transcript. A sequencing ladder of the corresponding genomic fragment, which was primed with the identical oligonucleotide, was electrophoresed in parallel. B, Transcriptional starts site identified by both primer extension (ϩ) and 5Ј-RACE (*) analysis. The putative TATA-like box is underlined. Note that both techniques identified a cDNA 110 nt shorter than previously reported (4). C, CAR promoter activity in HepG2 cells. A series of reporter constructs was generated containing 4711 bp of the 5Ј-flanking sequences from the hCAR gene. Smaller fragments generated using PCR amplification were linked to a luciferase reporter. The constructs were transfected into a human hepatocarcinoma cell line (HepG2). The luciferase activities from two separate transfections performed in triplicate were normalized to the ␤-galactosidase values.
tions outside of the putative GRE), hCAR-MUT2-pGL3TK (mutations in the 5Ј-half site), and hCAR-MUT3-pGL3TK (mutations in the 3Ј-half-site) were transfected in HepG2 cells in the presence or absence of hGR expression vector. Twenty-four hours later, cells were treated with 100 nM dexamethasone for 16 h. As shown in Fig. 7B , the hCAR-GREwt-pGL3TK and hCAR-GREinv-pGL3TK constructions were induced. Indeed, as expected for a classic enhancer, this element was able to function in both orientations to confer glucocorticoid responsiveness to this heterologous promoter. These inductions were dependent on hGR cotransfection (data not shown). Mutation of either putative half-site was sufficient to abolish transcriptional activation of the construct upon dexamethasone treatment. In contrast, the hCAR-MUT1-pGL3TK construct, where mutations were generated outside of the GGAACAacaAGGGCA motif, was still inducible. The hCAR promoter region Ϫ4458/Ϫ4425 acts as an enhancer, and is hereafter referred to as hCAR-GRE. However, this region was less responsive (3-fold induction) than the Ϫ4477/Ϫ4311 fragment (15-fold induction), whereas in contrast, the basal expression of the hCAR-GREwt-pGL3K or hCAR-GREinv-pGL3TK reporter constructs were approximately 10-fold stronger than the 4477/Ϫ4311pGL3TK construct (data not shown). These results suggest that additional sites within this fragment may increase the overall effect of GR action by affecting its accessibility to the GRE.
To determine whether GR interacts directly with this region, a gel shift analysis was performed with the 32 P-radiolabeled hCAR-GRE (Ϫ4458/Ϫ4425) oligonucleotide probe and baculovirus-expressed hGR. As shown in Fig. 8A , GR homodimers bound the CAR-GRE as a single complex (line 1), The specificity of the GR homodimer-hCAR-GRE interaction was demonstrated by competition studies. TAT-GRE oligonucleotide competed with the hCAR-GRE-GR complex (lines 7 and 8), with slightly greater efficiency than the hCAR-GRE itself (lines 3 and 4), whereas the TAT-GRE mutant did not (lines 5 and 6). In addition, the specific complex was supershifted with anti-GR antisera (line 2). Oligonucleotides corresponding to hCAR-GRE mutants 2 (lines 11 and 12) and 3 (lines 13 and 14) were not competitors for this binding, whereas hCAR-GRE mutant 1 was a good competitor (lines 9 and 10).
Using PCR-mediated mutagenesis, we confirmed that mutation of this motif (GTTACAacaATTGCA, mutations are underlined) resulted in the loss of dexamethasone responsiveness of the corresponding Ϫ4477/Ϫ4311GREmut-pGL3TK reporter compared Plasmids Ϫ4711/ϩ144pGL3b (harboring the 4.7-kb hCAR promoter) and the parental pGL3b were transfected into human hepatocytes in primary culture (HHPC), human hepatocarcinoma (HepG2), or monkey fibroblast (CV-1) with or without hGR expression vector (pSG5hGR). pSV-␤-galactosidase was added as internal control. Cells were treated with dexamethasone (black bars) or solvent (DMSO 0.1%, white bars) for 16 h. Cell extracts were assayed for luciferase activity, which was normalized to the ␤-galactosidase activity. Induction is expressed as the ratio of normalized luciferase in the presence of dexamethasone to this activity in the absence of dexamethasone. Error bars represent the SD of two independent experiments performed in triplicate.
with the native Ϫ4477/Ϫ4311pGL3TK construct (Fig.  8B ). These observations confirm that hCAR-GRE located between Ϫ4447 and Ϫ4432 nt upstream of the transcriptional start site binds to and is transactivated by ligand-activated hGR. To verify the in vivo relevance of the data obtained by both EMSA and transient-transfection assays in the context of chromatin in intact human hepatocyte cells, we performed a chromatin immunoprecipitation assay. We observed that only antibodies raised against hGR could efficiently immunoprecipitate the distal Ϫ4557 to Ϫ4157 region of the CAR promoter DNA. These observations were dependent on the presence of dexamethasone in the medium (Fig. 9) , suggesting stable in vivo association of the ligand-activated GR with the distal CAR promoter. In contrast, we failed to amplify a fragment corresponding to the proximal CAR promoter (Ϫ360 to ϩ144 region) after GR immunoprecipitation.
DISCUSSION
It is well established that glucocorticoids are required for the maintenance of cytochrome P450 expression and induction in hepatocytes. In addition, it is well known that PB induction of rat, mouse, or human CYP2B either requires or is potentiated by glucocorticoids (17, 18, 21, 22) ; however, glucocorticoids themselves are not inducers (3, 17, 30, 31) . The molecular mechanism of this phenomenon remained to be elucidated. One possible explanation is that glucocorticoids control the expression of transcription factors involved in both CYP expression and induction by xenobiotics. Mice deficient in CAR (CAR Ϫ/Ϫ ) show a complete loss of CYP2B and CYP3A induction in response to PB (13) . Thus, if CAR is a rate-limiting factor, increased expression of CAR by glucocorticoids would lead to the enhancement of the transcriptional activity of this receptor in the presence of its cognate activators. For example, in rat hepatocytes, glucocorticoids, such as dexamethasone, and PPAR activators synergically induce PPAR target genes, and notably those involved in lipid catabolism (32) . In fact, it has been reported that glucocorticoids directly activate the transcription of the PPAR␣ gene in vitro and in vivo (33, 34 ).
centrations of RU486 (100 and 1000 nM). Induction is expressed as the ratio of normalized luciferase in the presence of chemicals to this activity in the presence of solvent alone (0.2%). C, GR-DBD compete for hGR transactivation of CAR promoter. Plasmid Ϫ4711/ϩ144pGL3b was cotransfected into HepG2 cells with pSG5hGR and increasing amounts of the pCMV GR-DBD expression vector. Empty vector, pSG5 was added to keep the amount of DNA similar during transfections, and pSV-␤-galactosidase was added as an internal control. Twenty-four hours later, cells were treated and analyzed as indicated in Fig. 6A . Error bars represent the SD of two independent experiments performed in triplicate.
Fig. 5. Transactivation of CAR Promoter by GR
A, Plasmids Ϫ4711/ϩ144pGL3b and pTAT-GRE2-TK-luc (containing two copies of the GRE from TAT) were cotransfected into HepG2 cells with pSG5hGR and with pSV-␤-galactosidase as a transfection control. Cells were then treated with increasing concentrations of dexamethasone for 16 h. Induction of Ϫ4711/ϩ144pGL3b (black bars) is indicated by the left-hand scale and induction of the pTAT-GRE2-TK-luc (curve) is indicated by the right-hand scale. Induction is expressed as the ratio of normalized luciferase in the presence of dexamethasone to this activity in the presence of solvent alone (0.1%). B, Effect of RU486 on transactivation of CAR promoter by hGR. HepG2 cells were cotransfected with pSG5hGR and Ϫ4711/ϩ144pGL3b reporter vector. pSV-␤-galactosidase was added as internal control. Twenty-four hours later, cells were treated for 24 h with 100 nM dexamethasone or hydrocortisone and increasing con- A, Transactivation of homologous CAR promoter constructs by hGR. Plasmids harboring the CAR promoter constructs were cotransfected in HepG2 with pSG5 (white bars) or pSG5hGR (black bars). pSV-␤-galactosidase was added as internal control. hGR was activated by treatment of cells with 100 nM dexamethasone for 16 h. Cell extracts were assayed for luciferase activity, which was normalized to the ␤-galactosidase activity. Induction is expressed as the ratio of normalized luciferase in the presence of dexamethasone to this activity in the absence of dexamethasone. B, Transactivation of heterologous CAR promoter constructs by hGR. Plasmids harboring the CAR promoter linked to the pGL3TK constructs were cotransfected in HepG2 with pSG5 (white bars) or pSG5hGR (black bars). pSV-␤-galactosidase was added as internal control. Cells were treated and analyzed as indicated in Fig. 7A . Error bars represent the SD of three independent experiments performed in triplicate.
In previous work, we showed that expression of CAR in human hepatocytes is regulated by glucocorticoid hormones (17) . The involvement of transcriptional control through the classical glucocorticoid pathway was strongly suggested because 1) dexamethasone did not affect the degradation of CAR mRNA; 2) CAR mRNA induction was blocked by the glucocorticoid antagonist RU486; 3) the induction was not suppressed by cycloheximide treatment, indicating that it was mediated by preexisting GR; and 4) the RNA synthesis inhibitor actinomycin D abolished the stimulatory effect of dexamethasone. In this work, we cloned the hCAR regulatory region. The results of the analysis presented herein demonstrate transcriptional control of hCAR gene expression by glucocorticoids. Computer analysis of 4.7 kb of the hCAR 5Ј-regulatory region revealed the presence of numerous GRE halfsites, most of which was nonfunctional. In a first step, transient transfection studies suggested the presence of a glucocorticoid responsive unit located between Ϫ4477 and Ϫ4410 upstream of the transcription start. Indeed, the GRE that was characterized (Ϫ4447/ Ϫ4432) has a classical GRE structure, i.e. two halfsites separated by 3 nt, and mutations of this GRE in either half-site drastically decreased both binding and transactivation by hGR. These in vitro experiments were confirmed by a chromatin immunoprecipitation assay, as we found that dexamethasone treatment of cultured human hepatocytes causes binding of GR to this DNA region of the CAR promoter in intact cells. Of particular significance is that the murine CAR promoter gene contains a precise match to the human GRE (starting at chromosome 1, position 172485157), suggesting that similar glucocorticoid-dependent regulation should be observed in this species.
Interaction of this regulatory pathway with the CARmediated xenobiotic-signaling pathway suggests the existence of an activation cascade involving the following steps: 1) activation of the GR by glucocorticoids; 2) induction of the CAR gene by activated GR; 3) activation of the CAR by its cognate activators; 4) induction of the expression of CAR target genes by the activated CAR. According to this model, both glucocorticoids and CAR activators must be present for the cascade to work. Hence, it may explain the cooperative effect observed between glucocorticoids and PB and PB-like inducers on the expression of several CAR target genes (17, 18, 21, 22) , and the inhibitory effect of RU486 on PB-mediated CYP induction (21, 31, 35).
Fig. 7. Identification of the CAR-GRE
A, Sequence of the putative CAR-GRE of the hCAR promoter and oligonucleotides used for both transient transfection and gel shift assay analysis. The putative GRE half-sites are indicated in bold letters, whereas mutations generated are underlined. B, HepG2 cells were cotransfected with pSG5hGR and heterologous constructs containing one copy of the CAR-GRE wild type in normal (GREwt) or reverse orientation (GREinv) or mutated (MUT1, MUT2, MUT3) fused to the pGL3TK reporter vector. pSV-␤-galactosidase was added as internal control. Cells were treated and analyzed as indicated in Fig. 7A . Error bars represent the SD of two independent experiments performed in triplicate.
In vivo, such a regulatory cascade would be of great physiological significance because many CAR target genes are involved in the metabolism of xenobiotics, but also in the metabolism of endogenous compounds, such as steroids. Glucocorticoids would therefore have a permissive and even stimulatory function in this catabolism. Moreover, we might speculate that CAR expression in vivo would increase in situations where glucocorticoid hormone levels are high, e.g. in stress conditions or during the peak of the corticosterone circadian rhythm, as observed for PPAR␣ (33) . Finally, our finding that GR controls the expression of CAR, involved in the regulation of CYP gene expression mediating the oxidative metabolism of natural steroid hormones, may reveal the existence of a regulatory network governing endocrine GC ho-
Fig. 8. Identification of the CAR-GRE
A, Analysis of CAR-GRE binding to hGR by EMSA. Radiolabeled Ϫ4458/Ϫ4425 fragment (CAR-GRE) of the CAR promoter (50,000 cpm 32 P) was incubated in the presence of diethylaminoethyl-dextran-purified extracts of sf9 cells transfected with recombinant hGR baculovirus before loading onto the gel. In parallel experiments, incubation was performed in the presence of anti-hGR antibodies (␣GR, lane 2), 25-to 100-fold molar excess of unlabeled CAR-GRE (WT, lanes 3 and 4), 25-to 100-fold molar excess of unlabeled TAT-GRE wild type (GRE cons, lanes 7 and 8), or mutated in the GR-binding sites (GRE mut, lanes 5 and 6), 25-to 100-fold molar excess of unlabeled oligonucleotides corresponding to the MUT1 (lanes 9 and 10), MUT2 (lanes 11 and 12), or MUT3 (lanes 13 and 14), as defined in panel A. S., Shift; S.S, supershift. B, HepG2 cells were cotransfected with pSG5hGR and heterologous constructs corresponding to the native pGL3TK, the wild-type Ϫ4477/Ϫ4311-pGL3TK, or the mutated Ϫ4477/Ϫ4311GREmut-pGL3TK, where the GGAACAacaAGGGCA motif was changed to GTTACAacaATTGCA). pSV-␤-galactosidase was added as internal control. Cells were treated and analyzed as indicated in Fig. 7A . Error bars represent the SD of two independent experiments performed in triplicate.
meostasis. Moreover, in view of the well known functional interference between glucocorticoids and proinflammatory transcription factors such as activator protein 1 (Fos-Jun heterodimers), and nuclear factor-B (P65-p50 heterodimers), these results provide a possible explanation for the decrease of CAR expression (26) and PB-mediated CYP induction during infectious or inflammatory processes (23) (24) (25) .
MATERIALS AND METHODS
Materials and Reagents
DMEM was purchased from Invitrogen (Cergy Pontoise, France). Dexamethasone, mifepristone (RU486), hydroxycortisone, and dimethyl sulfoxide (Me 2 SO) were purchased from Sigma (Saint Quentin Fallavier, France). [␥-
32 P]ATP was purchased from Amersham (Amersham, UK).
Chromosomal in Situ Hybridization
Chromosomal localization was performed by FISH to highresolution metaphase chromosomes obtained from a phytohemagglutinin-stimulated blood cell culture of a healthy male (with his informed consent) with our usual technique (36) . The biotinylated MB67 cDNA (4) was used at a dilution of 25 ng/l. A second probe corresponding to the ϩ4711/ϩ144 region of the hCAR gene promoter (see below) was also used with the same technique at a dilution of 25 ng/l and competition with 5 g Cot1 DNA. The hybridization signals appeared as double yellow spots (fluorescein isothiocyanate) on red metaphase chromosomes (counterstained with propidium iodine and 4,6-diamidino-2-phenylindole to allow banding recognition).
RT-PCR and 5-RACE
Primary cultures of human hepatocytes were prepared and cultured on collagen-coated dishes (37) , and total RNA was isolated using Trizol reagent (Invitrogen) from 10 7 cells. For RT-PCR analysis, cDNA synthesis was performed using SuperScript reverse transcriptase (Invitrogen), random hexamer Human hepatocytes were treated for 24 h with either dexamethasone (100 nM) or DMSO (0.1%). Before immunoprecipitation, 5 l from each sample were used for PCR amplification of the distal (Ϫ4557/Ϫ4157) and proximal (Ϫ360/ϩ144) CAR promoter regions (input). The association of GR with the distal CAR promoter region was detected by immunoprecipitation with antibodies against GR (sc1002X or sc1003X from Santa Cruz Biotechnology, Inc.), followed by PCR amplification. As a control, sample lysates were also incubated without antibody (NoAb) or control rabbit IgG antibody (Control IgG).
primers, and 1 g of total RNA from human hepatocytes. One tenth of the cDNAs were directly used for PCR sets for the hCAR 5Ј-UTR according to the published cDNA sequence (4): UTR55-76 hCAR forward (5Ј-CCTAAGTCCATCCCTCAT-GAAA), UTR179-198 hCAR forward (5Ј-GGAGAGGCATTC-CATACCAG) and GSP1 hCAR reverse primer (5Ј-TCCTGAA-GAAACCCTTGCAG), corresponding to nt ϩ362 to ϩ381.
For 5Ј-RACE assay, cDNA was synthesized, using the 5Ј-RACE kit system (Invitrogen), from 10 g of human hepatocyte total RNA with GSP1 hCAR reverse primer. 5Ј-RACE PCR products were amplified using Abridged Anchor Primer (Invitrogen) and the GSP2 hCAR reverse primer, 5Ј-ACA-GATTTCCTACCTGCTTCTCTTAGGC, corresponding to nt ϩ228 to ϩ256 of the hCAR cDNA, and then cloned in pCR4-TOPO vector (Invitrogen). Sequencing reactions were performed using T3 primer and the BigDye sequencing kit (Perkin-Elmer Corp., Norwalk, CT).
Primer Extension Analysis
32 P-Labeled GSP2 hCAR oligonucleotide probe (10 M) was hybridized to 100 g of total RNA prepared from human hepatocytes in a buffer containing 40 mM piperazine-N,NЈ-bis(2-ethanesulfonic acid), pH 6.4; 1 mM EDTA; 0.4 M NaCl; and 80% formamide. The annealed products were precipitated and resuspended in a buffer containing 50 mM Tris, pH 8.3; 40 mM KCl; 6 mM MgCl 2 ; 1 mM dithiothreitol; 0.5 mM deoxynucleotide triphosphates; and 10 U of RnaseOut (Invitrogen). After addition of 10 U of SuperScript reverse transcriptase (Invitrogen), the reaction was allowed to proceed for 60 min at 37 C, followed by a 30-min digestion with 5 g of deoxyribonuclease-free ribonuclease (Roche Clinical Laboratories, Indianapolis, IN). The reaction products were extracted with phenol-chloroform, precipitated with ethanol, and electrophoresed in 5% polyacrylamide gels. A sequencing ladder of the corresponding genomic fragment generated with the Thermo Sequenase Cycle Sequencing Kit (Amersham), using the Ϫ4711/ϩ144pGL3b vector (see below) as a template and the 5Ј-32 P-labeled GSP2 hCAR primer, was electrophoresed in parallel.
hCAR Promoter Cloning and Reporter Constructions
Sequence information from the 5Ј-end of the hCAR locus was provided to us by the BLAST human genome project interrogation with the MB67 mRNA sequence (Z30425). A 4.9-kb fragment of hCAR 5Ј-flanking region was cloned in pCR-XL TOPO vector (Invitrogen) after amplification by PCR using human genomic male DNA (Promega Corp., Madison, WI) as a template and the Expand Long Template PCR System (Roche Clinical Laboratories). Nucleotides used were 5Ј-AG-TACATAAGACCCTAAGGATCCCCAAA and GSP2 hCAR primer. This plasmid was then digested by SacI/XhoI and the hCAR promoter fragment was subcloned in SacI/XhoI-linearized pGL3basic vector (Promega Corp.) upstream of the firefly luciferase coding region to generate the hCARϪ4710/ ϩ144pGL3b construct. The hCAR promoter was then totally sequenced (primer walking).
Homologous hCAR promoter deletions were obtained by PCR using SacI-hCAR forward 18-oligomer oligonucleotide primers and the reverse Glprimer2 (Promega Corp.) and the hCARϪ4710/ϩ144pGL3b plasmid as a template. Products PCR were then digested by SacI/XhoI and subcloned in SacI/ XhoI-linearized pGL3basic vector. pGL3TK plasmid was obtained by ligation of the HindIII/ BglII TK-SEAP vector (CLONTECH Laboratories, Inc., Palo Alto, CA) fragment, corresponding to the minimal 147 nt long TK promoter, into the HindIII/BglII-linearized pGL3basic vector. Heterologous constructs were generated by PCR using SacI-hCAR forward and XhoI-hCAR reverse 18-oligomer oligonucleotide primers and the hCARϪ4711/ϩ144pGL3b plasmid as a template. PCR products were then digested by SacI/XhoI and subcloned in SacI/XhoI-linearized pGL3TK vector.
Double-stranded oligonucleotides corresponding to the native hCAR GRE (5Ј-CCAACCAGAGGGAACAACAA GGG CAG TTGTTCA) and mutated (mutated bases are underlined) MUT1 (5Ј-CCATTCAGAGGGAACAACAAGGGCAGTTGTT-CA), MUT2 (5Ј-CCAACCAGAGGTTACAACAAGGGCAGTT-GTTCA), and MUT3 (5Ј-CCAACCAGAGGGAACAACAATTG-CAGTTGTTCA), were phosphorylated using T4 polynucleotide kinase (Invitrogen) and cloned into the pGL3TK vector digested with SmaI. Both inverse and native orientations of the hCAR-GRE region were generated (hCAR-GREwt-pGL3 and hCAR-GREinv-pGL3b) to test the glucocorticoid-responsive enhancer in reverse orientation and with a heterologous promoter.
Site-Directed Mutagenesis
Site-directed mutagenesis was performed using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) according to the method recommended by the manufacturer, and oligonucleotides 5Ј-CCAACCAGAGGT-TACAACAATTGCAGTTGTTCA and its reverse complement. The plasmid Ϫ4477/Ϫ4311 was used as template to generate the Ϫ4477/Ϫ4311GREmut-pGL3TK.
Other Plasmids
The pTAT-GRE2-TK Luc containing two copies of the consensus GRE upstream of a minimal simplex virus thymidine kinase promoter and a luciferase reporter gene, and the hGR DBD expression vector (pCMV GR-DBD) were kindly provided by Dr. L. Poellinger (Karolinska Institute, Stockholm, Sweden) and described elsewhere (38) . The hGR expression vector (pSG5-hGR) was kindly provided by Dr. J. C. Nicolas (INSERM, Montpellier, France). The pSG5 vector was from Stratagene (Amsterdam, The Netherlands).
Cell Culture, DNA Transient Transfections, and Reporter Gene Expression Assays
The HepG2 and CV1 cell lines were obtained from the NIH ATCC repository (Manassas, VA), and were propagated in DMEM plus 10% fetal bovine serum, nonessential amino acids, sodium pyruvate, and antibiotics (Invitrogen). Human hepatocytes, HepG2, and CV1 were transfected with fugene-6 transfection reagent (Roche Clinical Laboratories) according to the manufacturer's instructions. Briefly, 80,000 cells were transfected with 200 ng of reporter plasmid, 25 ng of pSV-␤-galactosidase control vector (Promega Corp.), and expression vector as mentioned in the legends to the figures. Twenty-four hours after transfection, cells were treated with the compounds indicated or 1:1000 (vol/vol) solvent [dimethylsulfoxide (DMSO)] in medium complemented with 5% delipidated and charcoal-stripped bovine calf serum (Sigma). Thirty-six hours later, cells were washed in 1ϫ PBS and lysed in Lysis Buffer (Promega Corp.). Luciferase and ␤-galactosidase assays were performed according to the specifications of the manufacturer (Promega Corp.). Plasmid DNAs were purified using the Nucleobond DNA isolation system from Macherey-Nagel (Duren, Germany).
EMSA
EMSAs were performed using 5Ј-32 P-labeled doublestranded oligonucleotide 5Ј-CCAACCAGAGGGAACAA-CAAGGGCAGTTGTTCA. Fifty thousand counts per minute were incubated as described elsewhere (14) with 4 g of total protein from Sf9 cells transfected with a recombinant GRexpression baculovirus (kindly provided by F. Cadepond).
